Clinical Trials
13 trialsNCT05485831 2026-06-03
EpiTALY
Jazz Pharmaceuticals
Active not recruiting
NCT05864846 2026-04-27
EpiCom
Jazz Pharmaceuticals
Phase 4 Completed
NCT02962414 2026-04-02
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Novartis
Phase 3 Active not recruiting
NCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT05059327 2025-06-04
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Noema Pharma AG
Phase 2 Completed
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT01977651 2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT02544763 2022-09-28
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT02544750 2022-07-14
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT04450160 2020-06-29
AEO
MetVital, Inc.
Phase 2 Unknown
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed